Roche Secures Promising Bowel Disease Therapy—Which Could Help Treat Crohn’s—In $7.1 Billion Telavant Deal
The Swiss pharma giant said it will begin late-stage trials on the experimental antibody therapy “as soon as possible” to help bring it to patients suffering from inflammatory bowel disease.
The Swiss pharma giant said it will begin late-stage trials on the experimental antibody therapy “as soon as possible” to help bring it to patients suffering from inflammatory bowel disease.
What's Your Reaction?
